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HIV-1 envelope proteins gp120 and gp41 are likely to play a role in the pathogenesis of HIV-associated neurocognitive
disorders. While detection of gp120 in HIV-infected cell cultures is easy, it has not yet been possible to identify gp120 in
human or animal brains in situ. The difficulty in detecting gp120 could be due to low expression levels of the protein, to the
shedding of gp120 from infected macrophages/microglia, or to the use of inappropriate gp-specific antibodies. We addressed
these questions by analyzing the subcellular localization, oligomeric structure, and shedding behavior of gp120 from a
macrophage-tropic, CCR5-dependent primary isolate, BX08, expressed by a Semliki Forest virus replicon (SFVenvBX08) in
vitro. We used the same SFV system injected in vivo into the rat brain in an attempt to detect gp120 in situ. Our results show
that gp120/41 is expressed as monomers, dimers, and trimers in cell culture. Immunocytochemical analysis revealed that
intracytoplasmic gp120 can be recognized by an anti-V3 antibody, whereas gp120 at the plasma membrane is detected
exclusively by a conformation-dependent antibody. In the rat brain, the SFV vector allows gene expression in neurons from
day 3 to day 9 after injection without any apparent brain damage nor reactive astrogliosis. In SFVenvBX08-infected neurons
only conformation-dependent antibodies allowed gp120 labeling. These results suggest that previous difficulties in detecting
gp120 in brain tissues may be due to the use of antibodies which were unable to recognize gp120 at the plasma membrane.
© 1999 Academic Press
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TINTRODUCTION
In the human immunodeficiency virus (HIV)-infected
ell, the envelope glycoproteins are synthesized as an
45- to 870-amino-acid precursor, in the rough endoplas-
ic reticulum. Asparagine-linked, high-mannose sugar
hains are added to form the gp160 glycoprotein, which
ssembles into oligomers. The gp160 oligomers are
ransported to the Golgi apparatus, where cleavage by a
ellular protease generates the mature envelope glyco-
roteins: gp120, the extracellular envelope glycoprotein,
nd gp41, the transmembrane glycoprotein. Both glyco-
roteins are maintained in the assembled oligomer by
oncovalent interactions. The gp41 glycoprotein has a
ong cytoplasmic tail, a membrane-spanning anchor, and
n ectodomain, which has been shown to form trimers
Chan et al., 1997; Lu et al., 1995). Most of the surface-
xposed elements of the mature, oligomeric envelope
lycoprotein complex are contained on the gp120 moiety.
IV infection requires the interaction of the gp120 enve-
ope glycoproteins with specific receptors, the CD4 gly-
oprotein and members of the chemokine receptor fam-
ly. Studies of chimeric envelope glycoproteins demon-
trated that the third variable (V3) loop of gp120 is a
1 The first two authors contributed equally to this work.
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314ajor determinant of interaction with chemokine recep-
ors (Cocchi et al., 1996).
Patients infected with human immunodeficiency virus
ype 1 (HIV-1) often develop neurological problems, in-
luding cognitive and motor deficits (for review see Grant
t al., 1995; Gray et al., 1996; Lipton and Gendelman,
995; Sacktor and McArthur, 1997; Trillopazos and
verall, 1996). The cells predominantly infected by HIV-1
n the brain are from the macrophage/microglial lineage.
either astrocytes nor neurons appear to be productively
nfected with HIV-1. There is accumulating evidence to
uggest that neuronal dysfunction and death involve a
umber of viral and host factors. Among them, the HIV-1
nvelope proteins gp120 and gp41 are likely to play a
ignificant role in the pathogenesis of the disease (for
eview see Dubois-Dalcq et al., 1995; Lipton and Gen-
elman, 1995).
While detection of gp120 in HIV-infected cell cultures
s easy, it has not yet been possible to demonstrate the
resence of gp120 in the brain of HIV-1-infected humans
Adamson et al., 1996) nor in that of transgenic mice,
lthough mRNA for gp120 could be detected in mouse
rains (Toggas et al., 1994). In contrast, the transmem-
rane glycoprotein gp41 is commonly detected on brain
ections from HIV-seropositive patients. Several expla-
ations can be put forward to account for these results.
he difficulty in detecting gp120 in brain tissues could be
ue to low expression levels of the protein, to the shed-
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315DETECTION OF MACROPHAGE-TROPIC HIV-1 gp120 IN BRAINing of gp120 from infected macrophages/microglia, or
o the use of inappropriate gp-specific antibodies.
In the present work we have reexamined these issues
y analyzing the subcellular localization, oligomeric
tructure, and shedding behavior of gp120/41 from a
acrophage-tropic, CCR5-dependent primary isolate,
X08 (Verrier et al., 1997), expressed from defective Sem-
iki Forest virus (SFV) replicons in BHK-21 cells in vitro.
e have also used the same SFV expression system
njected in vivo into the rat brain in an attempt to detect
p120 in situ. Immunocytochemical analysis revealed
hat cytoplasmic gp120 is recognized by an anti-V3 anti-
ody, whereas the plasma membrane-associated form is
etected exclusively by a conformation-dependent anti-
ody, 2G12 (Trkola et al., 1996). In vivo, in SFV-infected rat
rains, only conformation-dependent antibodies allowed
p120 labeling in neurons. This suggests that previous
ifficulties in detecting gp120 in situ are most likely due
o the use of antibodies which were unable to recognize
he oligomeric, membrane-bound form of the HIV enve-
ope glycoprotein at the plasma membrane.
RESULTS
ligomerization of gp120/41
Western blot analysis was performed under nondena-
uring conditions on cellular extracts and supernatants of
HK cells infected with SFVenvBX08 (Fig. 1). In the su-
ernatant, gp120 could be detected as a monomer using
he anti-V3 antibody K24 as well as the conformation-
ependent human monoclonal antibody 2G12. The same
ntibodies revealed gp120 in the cell extracts in four
ifferent forms, monomeric gp120 and mono-, di-, and
rimeric gp160. There was no evidence for selective rec-
gnition of gp120/41 oligomers by anti-V3 or conforma-
FIG. 1. Oligomers of gp120/41. BHK cells were infected with
FVenvBX08 for 20 h prior to cell extraction. Extracts (lanes a and c)
nd supernatants (lanes b and d) were run on SDS–PAGE gradient gels
4–12%), blotted, and subjected to immunodetection using anti-V3 mAb
24, lanes a and b, or the conformation-dependent mAb 2G12, lanes c
nd d. The positions of monomeric gp120 and mono-, di-, and trimeric
p120/41 are indicated.ion-dependent antibodies on Western blot. nubcellular localization of gp120 in BHK cells
Immunocytochemistry and confocal laser microscopy
ere used to analyze the subcellular localization of
p120 in SFVenvBX08-infected BHK cells. With the
nti-V3 antibody K24, labeling was observed in the cyto-
lasm, thus revealing the intracellular form of gp120 (Fig.
A). In contrast, conformation-dependent mAb 2G12 rec-
gnized gp120 at the plasma membrane (Fig. 2B). These
esults suggest that the BX08 V3 loop was not exposed
n gp120/41 oligomers at the cell surface, in accordance
ith results showing resistance of primary HIV isolates
o neutralization with anti-V3 antibodies (Sullivan et al.,
995).
FV-mediated gene expression in the brain
SFVlacZ or SFVenvBX08 particles were injected ster-
otaxically into the prefrontal cortex and the striatum of
dult rat brains and immunohistochemistry was per-
ormed for the heterologous gene products. Immuno-
taining using antibodies specific for b-galactosidase
evealed that SFV can be used as an expression vector
n the rat brain. As shown in Fig. 3A, in slices taken from
he prefrontal cortex 3 days after infection, b-galactosi-
ase staining was observed in cells surrounding the
njection site and up to 500 mm away. Intense staining
as evident in the soma and processes of cells exhibit-
ng typical neuronal morphology, in particular pyramidal
ells with apical dendritic tree reaching the superficial
ortical layers (Fig. 3B). Similarly, in the striatum (Fig. 3C),
-galactosidase staining filled the whole neuron and
elineated its processes, including dendritic arborization
nd synaptic boutons. It is noticeable that although b-ga-
actosidase gene expression is targeted to the nucleus,
he protein was detected in the cytoplasm, which is
robably indicative of a high level of protein expression
nd diffusion into the whole neuron. No labeling of cells
ith a microglial or astrocytic morphology was observed.
When using conformation-dependent anti-gp120 hu-
an mAbs such as 2G12, immunoreactive cells were
bserved around the injection sites, on day 3 following
FV injections into the prefrontal cortex (Fig. 3D) and the
triatum. Similar results were obtained with mAbs 670-D
nd 694/98D (data not shown). In contrast, anti-V3 mAbs,
uch as K24 and F5.5, failed to produce any detectable
ignal (Fig. 3E). It might be argued that the lack of
mmunodetection with anti-V3 mAbs in brain tissue was
ue to V3 epitope damage as a consequence of oxida-
ion during the H2O2 pretreatment or to prolonged para-
ormaldehyde (PFA) fixation. This hypothesis can be ex-
luded as gp120 is still detected by anti-V3 mAbs in BHK
ells subjected in vitro to the same treatment as brain
lices (Fig. 2C).
As observed for b-galactosidase staining, the cell type
mmunoreactive for gp120 could be clearly identified as
eurons (Fig. 3F). This was confirmed by immunofluores-
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316 ALTMEYER ET AL.ent colabeling with the neuronal marker MAP2 (Fig. 4).
n all sections examined, intense gp120 staining was
bserved in the soma and the neuronal processes (Figs.
F and 3G). However, dendritic spines were not always
s clearly delineated as with b-galactosidase staining
compare Figs. 3C and 3G). This may be tentatively
ttributed to differences in diffusion properties between
he two molecules. Compared to b-galactosidase,
p120/41 is less prone to diffusion in the cytoplasm due
o its membrane targeting.
FIG. 3. SFV-mediated gene expression in the rat brain. Rats were
refrontal cortex and the striatum. After 3 days, brains were proces
nti-gp120 mAbs 2G12 (D, F, and G) or K24 (E). (A) Section from th
urrounding the site of injection. The left edge of the picture correspon
rea Cg3). (B) Higher magnification of the section in A showing b-galac
xternal cortex. (C) A high-power view of a b-galactosidase-positive ne
D) Cross section through the left and right interhemispheric borders of
ite in the left prefrontal cortex using the 2G12 mAb. In the right prefro
taining is observed in the left prefrontal cortex when the anti-gp120 m
eurons using 2G12 mAb. (G) Higher magnification of the striatal slice in
FIG. 2. Subcellular localization of gp120. BHK-21 cells were infected
eriod (15 min) and then processed for immunocytochemistry with mAb
nd H2O2 treatment prior to incubation with antibody. FITC fluorescencars in A, D, and E, 300 mm; in B and F, 60 mm; in C and G, 3 mm.It is noteworthy that in slices including the striatum, we
id not detect any labeling in the surrounding cortex,
hich might have been indicative of retrogradely trans-
orted virus along corticostriatal pathways.
ime course of SFV-mediated gene expression
n the brain
To study the longevity of SFV-mediated gene expres-
ion in the rat brain, we compared b-gal and gp120
taxically injected with SFVlacZ (A–C) or SFVenvBX08 (D–G) into the
r immunohistochemistry using anti-b-galactosidase mAb (A–C) and
prefrontal cortex showing numerous b-galactosidase-positive cells
he interhemispheric border of the anterior prefrontal cortex (prelimbic
e staining in pyramidal neurons whose dendritic processes reach the
om the striatum. Note the well-delineated staining of dendritic spines.
efrontal cortex showing gp120-immunoreactive cells near the injection
rtex is the trace of injection of SFVlacZ. (E) Section adjacent to D. No
is used. (F) Section from the striatum showing gp120-immunoreactive
ing strong gp120 staining in the soma and neuronal processes. Scale
FVenvBX08 for 16 h. In A and B, cells were fixed with PFA for a short
) or mAb 2G12 (B). In C, cells were subjected to overnight PFA fixation
sity is represented as an artificial color scale.stereo
sed fo
e right
ds to t
tosidas
uron fr
the pr
ntal co
Ab K24
F showwith S
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318 ALTMEYER ET AL.mmunostaining at days 3, 5, 9, and 12 after SFV vector
njections. Expression was strongest at 3 to 9 days after
njection, with a marked decline by 12 days, when only
ery few immunoreactive cells were observed (data not
hown). No qualitative difference in the decline of b-ga-
actosidase and gp120 expression could be detected.
FAP immunohistochemistry
Antibodies specific for the astrocytic marker GFAP
ere used to determine whether the injection proce-
ures and/or in situ expression of heterologous proteins
nduced inflammatory reactions. Figure 5 shows typical
xamples of GFAP immunoreactivity as observed 3 days
fter injections into the prefrontal cortex. In control rats
eceiving a buffer injection in a single hemisphere (Fig.
A), GFAP staining surrounding the needle tract did not
arkedly differ from the intact tissue in the contralateral
emisphere (Fig. 5A). This confirms the limited tissue
amage observed around the needle tract at day 3
ostinjection.
In rats receiving SFVlacZ into the right hemisphere
nd SFVenvBX08 into the left hemisphere (Fig. 5B), no
bvious increase of GFAP staining over control could be
etected. Similarly, in animals injected with SFV particles
n one hemisphere and with buffer in the contralateral
FIG. 4. Colocalization of immunofluorescence staining for gp120 and t
he prefrontal cortex were stained simultaneously with human mAb 2G
reen. Scale bar, 3 mm.emisphere, GFAP immunoreactivity did not significantly oiffer between the two injection sites (data not shown).
hus, gene expression via the SFV vector was not asso-
iated with any obvious activation of astrocytes, at least
rom day 3 to day 9 after injection.
DISCUSSION
xpression and detection of HIV-1BX08gp120 in vitro
nd in vivo
Our experiments show that expression of gp120/41
rom a primary HIV-1 isolate using the SFV replicon
ystem in BHK-21 cells results in the formation of four
ifferent molecular entities containing gp120. The appar-
nt molecular weight of these proteins in SDS–PAGE
dentifies them as monomeric gp120 and monomers,
imers, and trimers of gp120/41. A small fraction of gp120
s released from plasma-membrane-bound gp120/41 into
he supernatant. We have not observed more complex
orms of gp120/41 such as the tetramers previously de-
cribed for soluble gp160 (Earl and Moss, 1993; VanCott
t al., 1995) or gp41 (Shugars et al., 1996). It cannot be
xcluded that under the experimental conditions used
ere, tetramers which dissociated during SDS–PAGE
nd Western blot procedures were formed. The obser-
ation that gp120/41 could be recovered under the form
ronal marker MAP2. At day 3 after SFVenvBX08 injection, sections from
and mouse mAb anti MAP2 (A). gp120 is labeled in red and MAP2 inhe neuf trimers is in accordance with X-ray crystallography
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319DETECTION OF MACROPHAGE-TROPIC HIV-1 gp120 IN BRAINata demonstrating the formation of trimers by the gp41
ctodomain (Chan et al., 1997; Lu et al., 1995; Weissen-
orn et al., 1997). Similar observations have been made
n the laboratory showing trimeric forms of gp140BX08,
hich lacks the transmembrane region and the intracy-
FIG. 5. GFAP immunoreactivity at day 3 following injections into the p
y buffer injection into the left prefrontal cortex. No obvious difference
ortex. (B) GFAP immunoreactivity after injection of SFVenvBX08 into
ifference in GFAP labeling can be detected between the two injectiooplasmic domain of gp41 (Staropoli et al., manuscript in mreparation). Remarkably, these trimers were resistant to
DS and boiling and could be dissociated only with
educing agents.
Using immunocytochemistry and confocal laser mi-
roscopy we observed that the conformation-dependent
al cortex. (A) GFAP staining around the trace of the needle tract made
ing is observed compared with the intact tissue of the right prefrontal
prefrontal cortex and of SFVlacZ into the right cortex. No significant
Scale bar, 300 mm.refront
in stain
the leftAb 2G12 bound specifically the gp120 molecules lo-
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320 ALTMEYER ET AL.ated at the cell surface. This antibody is known to
eutralize a broad variety of laboratory-adapted and pri-
ary HIV-1 isolates from divergent HIV-1 subtypes
Trkola et al., 1995). In contrast, V3-specific mAbs such
s K24 failed to recognize gp120 at the cell surface and
etected only the intracellular forms of the molecule. It
as previously been shown that glycosylation is impor-
ant for 2G12 binding to gp120 (Trkola et al., 1995). Thus,
emoval of N-linked carbohydrates in constant (C2, C3,
nd C4) and variable (V4) regions of the protein destroys
he 2G12 epitope. The HIV envelope protein is progres-
ively glycosylated following translocation of the nascent
olypeptide chain to the endoplasmic reticulum (ER).
lycosylation starts in the ER and continues through the
olgi network. Initial glycosylation events in the ER pre-
ede proper folding of the monomer, formation of disul-
ide bridges, and oligomerization. Cleavage of the pre-
ursor gp160 into gp120 and gp41 takes place in the
olgi. Maturation of the molecule is completed by late
lycosylation events in the trans-Golgi before transport
o the plasma membrane. Our results suggest that K24
ecognizes the V3 loop on the nascent, un- or partially
lycosylated molecule in the ER and Golgi prior to cor-
ect folding of the monomeric chain. Subsequent oli-
omerization of the envelope might lead to partial or
omplete inaccessibility of the V3 loop, resulting in the
oss of K24 reactivity. Glycosylation of gp120 in the trans-
olgi could also contribute to the masking of the V3
pitope by sugar moieties in the terminally processed
olecule at the cell surface. Along this line, the gain of
eactivity of 2G12 with gp120 at the plasma membrane
ould be explained by late glycosylation events of the C2,
3, C4, and V4 regions in the trans-Golgi, allowing for-
ation of the 2G12 epitope. Alternatively, one could hy-
othesize that the proper tertiary structure of the enve-
ope protein necessary for recognition by 2G12 is not
stablished until late in the maturation process, i.e., near
r at the plasma membrane. Our observations might
xplain why mAb K24, in contrast to 2G12, was unable to
nhibit gp120/41BX08-mediated cell-to-cell fusion (Verrier et
l., 1997). Similarly, neutralization studies have shown
hat V3-loop-specific mAbs have a poor neutralizing ef-
ect on macrophage-tropic HIV-1 isolates (Sullivan et al.,
995).
In view of these results obtained in BHK-21 cell cul-
ure, we hypothesized that previously reported failures to
etect gp120 in the brain (Adamson et al., 1996; Toggas
t al., 1994) might be due to the use of antibodies that
ere unable to recognize the oligomeric forms of gp120
t the plasma membrane. Therefore SFVenvBX08 was
njected into the rat brain and various mAbs were tested
y immunohistochemical staining on tissue sections.
euronal cells surrounding the injection site were
eadily stained with human conformation-dependent
Abs 2G12, 670-D, and 694/98D, which are capable ofnhibiting gp120/41BX08-mediated cell-to-cell fusion. In sontrast, no staining was observed when using mouse
Abs K24 or F5.5, which are directed against the V3 loop
Verrier et al., 1997). This suggests that SFV-mediated
xpression of gp120/41 in the brain led to the synthesis
f a plasma-membrane-bound gp120 with a native oligo-
eric conformation. Two explanations can be proposed
o account for the lack of detection of gp120 using anti-V3
Abs: (i) gp120 was predominantly present as an oligo-
eric protein at the cell surface on which the V3 loop is
ot accessible to antibodies or (ii) intracellular levels of
he protein were too low to be detected by anti-V3 mAbs.
he same explanations may apply to the situation in
IV-infected human brains. Thus conformation-depen-
ent anti-gp120 mAbs may be useful to identify gp120 in
uman brains and help to get more insight into the role
f gp120 in the neuropathology of HIV infection. How-
ver, our attempts to detect gp120 in autopsy brain tis-
ues from AIDS patients have not been conclusive, as
abeling with human mAb 2G12 results in nonspecific
taining of monocyte/macrophages and astrocytes.
p120-specific conformation-dependent mAbs produced
n nonhuman species are needed to avoid nonspecific
mmunoreactivity inherent to the use of human mAb on
uman tissue.
p120 and neuropathology
The neuropathological features in HIV-infected brains
nclude multinucleated giant cells, microglial nodules,
euronal loss, myelin pallor, and astrogliosis, the latter
eing the omnipresent feature (Adamson et al., 1996;
ray et al., 1996; Trillopazos and Everall, 1996).
We have observed that from day 3 to day 9 after
ntracerebral injection of SFVenvBX08, expression of
p120 in neurons did not cause any apparent brain
amage nor reactive astrogliosis, as attested by the
bsence of increased GFAP expression. It might be ar-
ued that the lack of astrogliosis was due to the transient
xpression of gp120/41 in our system. However, in trans-
enic mice with sustained neuronal expression (under
he human neurofilament gene promoter) of the entire
IV genome or of gp120/41, no or only limited signs of
strogliosis could be observed (Berrada et al., 1995;
homas et al., 1994). Similarly, minor brain alterations
ave been reported following intracerebral injections of
p120 into rats (Bagetta et al., 1996; Barks et al., 1995).
hese observations are in contrast with the marked
athological effects in neurons, astrocytes, and microglia
bserved in transgenic mice (Toggas et al., 1994) ex-
ressing soluble gp120 in astrocytes (under the GFAP
romoter). Several explanations, not mutually exclusive,
ay be proposed to account for these conflicting results:
1) gp120 expression by glial cells is more prone to
rigger neurotoxic processes than neuronal expression.
here is strong evidence from in vitro and in vivo data to
uggest that gp120 neurotoxicity involves specific inter-
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321DETECTION OF MACROPHAGE-TROPIC HIV-1 gp120 IN BRAINctions between HIV-infected macrophages, astrocytes,
nd neurons. For example, gp120 toxicity is not observed
n pure neuronal cultures but requires the presence of
acrophages which are stimulated by gp120 to release
oxic factors like nitric oxide (Adamson et al., 1996; Daw-
on et al., 1993; Lipton and Gendelman, 1995). gp120
lso affects astrocyte functions such as glutamate up-
ake (Benos et al., 1994), activation of potassium chanels
Bubien et al., 1995), and upregulation of intercellular
dhesion molecule-1 expression (Shrikant et al., 1996).
aken together, these results suggest that gp120 expres-
ion in neurons does not induce neurotoxic effects. (2)
he soluble form of gp120 is more neurotoxic than the
embrane-bound form. This could explain why neuropa-
hology is more pronounced in transgenic mice express-
ng soluble gp120 in astrocytes (Toggas et al., 1994) than
n mice expressing membrane-bound gp120/41 (Berrada
t al., 1995). Thus gp120 would have to be released into
he extracellular space in order to be neurotoxic. In that
ase, the extracellular concentration of gp120 would be
critical factor for neuropathology. Indeed, if only a
imited amount of gp120 was released into the extracel-
ular space, as observed with the SFV replicon in vitro,
his might not be sufficient to trigger neurotoxic pro-
esses. It has been shown that gp120 may be active in
itro at picomolar concentrations. In vivo, the question of
he active concentration is still unanswered as methods
mployed in brain tissues (immunohistochemistry, West-
rn blotting, enzyme-linked immunosorbent assay) are
ot sensitive enough to detect picomolar concentrations
Lipton and Gendelman, 1995).
In conclusion, our results showing that gp120 expres-
ion in neurons did not induce marked pathological ef-
ects support the view that gp120 is not directly toxic to
eurons and that neuronal injury is rather mediated by
omplex cellular interactions involving activation of glial
ells.
FV as an expression vector in neurons
The SFV vector has been successfully used in neuro-
al cell cultures to express membrane-bound glycopro-
eins such as amyloid protein precursor (De Strooper et
l., 1995). Our results demonstrate that SFV is a suitable
ector for expressing foreign proteins in neuronal cells in
ivo. Protein expression persisted for 9 days after infec-
ion, indicating the absence of cytopathic effect in the
nfected neuron during this time interval. The mecha-
isms involved in the decline of gene expression, as
bserved by day 12, are currently under investigation. It
s important to note that the presence of SFV in the brain
as not accompanied by obvious signs of host inflam-
atory response as opposed to other types of viral
ectors such as adenovirus (Byrnes et al., 1996).
As a whole, the SFV vector appears to be a promising pool for in vivo gene delivery to neuronal cells and ex-
ression of proteins in a biologically active form.
MATERIALS AND METHODS
ell culture and production of recombinant SFV
articles
BHK cells were grown in GMEM medium (Gibco) sup-
lemented with 5% fetal calf serum and 10% tryptose
hosphate. Recombinant Semliki Forest virus stocks
ere prepared as previously described (Liljestro¨m and
aroff, 1991; Verrier et al., 1997). pSFVlacZ codes for the
scherichia coli b-galactosidase fused to a nuclear lo-
alization signal (Liljestro¨m and Garoff, 1991). The entire
nv gene of the macrophage-tropic HIV-1 isolate BX08
as inserted into the BamHI site of plasmid pSFV-1,
esulting in plasmid pSFVenvBX08 (Verrier et al., 1997). In
itro-transcribed RNA from recombinant SFV plasmids
nd pSFVHelper2 RNA were transfected into BHK cells
y electroporation (830 V, 25 mF, V`) using a Bio-Rad
ene pulser. Recombinant, defective viral particles were
arvested 24 h later and concentrated by ultracentrifu-
ation. Prior to infection of BHK cells or injection into rat
rains, recombinant SFV particles were activated by chy-
otrypsin digestion (Berglund et al., 1993).
estern blot and immunocytochemistry
BHK cells were infected with SFVenvBX08 with a mul-
iplicity of infection of 5. Cell extracts were prepared with
% octylglucoside and analyzed on 4–12% SDS–PAGE
radient gels under nonreducing conditions. For immu-
ocytochemistry, cells were fixed with 4% PFA for 15 min
t 4°C prior to labeling with antibodies. In some exper-
ments, designed to test the influence of fixation condi-
ions on immunoreactivity compared to brain sections,
FVenvBX08-infected BHK cells were fixed overnight in
% PFA followed by incubation in blocking solution con-
aining 0.2% gelatin and 0.1% Triton X-100 for 30 min at
oom temperature in 13 PBS. Cells were then incubated
n 0.3% hydrogen peroxyde in methanol for 20 min at
20°C prior to incubation with antibody. gp120 was
etected using either mouse anti-V3 mAb K24 (Hybri-
olab, Institut Pasteur) or conformation-dependent hu-
an mAb 2G12 (Trkola et al., 1996). Specific binding was
evealed with biotin–avidin (Vector) and peroxidase/dia-
inobenzidine (DAB) for Western blots and fluorescein
FITC) for immunofluorescence. FITC-labeled cell cul-
ures were analyzed by confocal laser microscopy
Zeiss).
nimals and stereotaxic SFV injections
Male adult Long Evans rats (250–300 g) were anes-
hetized (sodium pentobarbital, 50 mg/kg) and positioned
n a stereotaxic frame. Holes were drilled in the appro-
riate location in the skull and a 5-ml Hamilton syringe
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322 ALTMEYER ET AL.ith a needle was used to inject 2 ml of SFV vector
uspension (106 infectious particles) into the prefrontal
ortex (AP 13.5, LAT 10.5, DV 24) and into the striatum
AP 11.6, LAT 12, DV 26). The injection was performed
t a rate of 0.5 ml/min for 4 min. At the cessation of the
njection, the needle was left in place for 5 min before
ithdrawal. The SFV suspension remaining in the sy-
inge was then collected and assayed on BHK-21 cells
or expression of b-galactosidase or EnvBX08. Rats were
ivided into four groups: group 1 received SFVlacZ in the
ight hemisphere (RH) and SFVenvBX08 in the left hemi-
phere (LH), group 2 received SFVlacZ in the LH and
uffer in the RH, group 3 received SFVenvBX08 in the LH
nd buffer in the RH, and group 4 received buffer in the
H and the RH was left intact. During the 3 to 12 days
ollowing brain injections, no gross behavioral abnormal-
ties in daily activities or changes in body weight could
e detected between groups.
rain tissue processing and immunohistochemistry
Between 3 and 12 days after the SFV injection, rats
ere perfused transcardially with 4% PFA in phosphate-
uffered saline, pH 7.4. Brains were removed and post-
ixed overnight in fixative solution at 4°C. Brain sections
f 40-mm thickness were cut on a Vibratome (Leica).
oronal sections were taken from the full extent of the
refrontal cortex and the striatum.
Floating sections were rehydrated in blocking solution
ontaining 0.2% gelatin and 0.1% Triton X-100 in 13 PBS
or 30 min at room temperature. Sections were then
ncubated in 0.3% hydrogen peroxyde in methanol for 20
in at 220°C. Brain sections were incubated overnight
t room temperature with primary antibodies (5 mg/ml)
irected against b-galactosidase (Boehringer Mann-
eim) or gp120 using either mouse anti-V3 mAb K24 or
5.5 (Hybridolab, Institut Pasteur) or with conformation-
ependent human mAbs 2G12 (Trkola et al., 1996), 670-D
Zolla-Pazner et al., 1995), or 694/98D (Gorny et al., 1992).
ections were then incubated with the appropriate bio-
inylated secondary antibodies (Vector Laboratories).
igh-affinity interaction between immune complexes
nd peroxidase were revealed with DAB.
For double-labeling experiments, a neuron-specific
ouse mAb directed against MAP2 (Boehringer Mann-
eim) and a gp120-specific human mAb (2G12) were
sed. Immune complexes were revealed using the ap-
ropriate secondary antibodies labeled respectively with
ITC for MAP2 and rhodamine (Vector) for gp120 detec-
ion.
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